Siltuximab: a new option for the management of Castleman's disease.

Abstract

Castleman's disease is a rare lymphoproliferative disorder the underlying mechanism of which remains unclear. However, interleukin-6 (IL-6) may play a role in the pathogenesis of the disease. Blockade of the IL-6 pathway has been explored in multiple preclinical and clinical studies with promising results for the treatment of different types of cancer and Castleman's disease. Siltuximab is a human/murine chimeric immunoglobulin G1kappa (IgG1kappa) monoclonal antibody against human IL-6. It binds to IL-6 neutralizing its biological activity. Recent phase II clinical studies in patients with multicentric Castleman's disease have shown the efficacy and safety of siltuximab in patients with this condition. Results from this study led to the recent approval of siltuximab for the treatment of Castleman's disease by the FDA and EMA.

• Authors: N Barquero
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 51 Issue 1 Pg. 21-8 (Jan 2015) ISSN: 1699-3993 [Print] Spain
• PMID: 25685858 (Publication Type: Journal Article, Review)
• Copyright: Copyright 2015 Prous Science, S.A.U. or its licensors. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• IL6 protein, human
• Immunosuppressive Agents
• Interleukin-6
• siltuximab

Topics

• Animals
• Antibodies, Monoclonal (adverse effects, pharmacokinetics, therapeutic use)
• Castleman Disease (drug therapy, immunology, metabolism, pathology)
• Drug Interactions
• Humans
• Immunosuppressive Agents (adverse effects, pharmacokinetics, therapeutic use)
• Interleukin-6 (antagonists & inhibitors, immunology, metabolism)
• Signal Transduction (drug effects)
• Treatment Outcome